X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs IPCA LABS - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD IPCA LABS BIOCON LTD/
IPCA LABS
 
P/E (TTM) x 94.2 36.4 258.7% View Chart
P/BV x 7.7 3.5 222.4% View Chart
Dividend Yield % 0.2 0.1 108.5%  

Financials

 BIOCON LTD   IPCA LABS
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
IPCA LABS
Mar-17
BIOCON LTD/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,162643 180.7%   
Low Rs483503 96.0%   
Sales per share (Unadj.) Rs194.6254.4 76.5%  
Earnings per share (Unadj.) Rs34.416.1 214.1%  
Cash flow per share (Unadj.) Rs48.329.8 162.1%  
Dividends per share (Unadj.) Rs1.001.00 100.0%  
Dividend yield (eoy) %0.10.2 69.7%  
Book value per share (Unadj.) Rs241.9194.6 124.3%  
Shares outstanding (eoy) m200.00126.20 158.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.22.3 187.7%   
Avg P/E ratio x23.935.7 67.0%  
P/CF ratio (eoy) x17.019.2 88.5%  
Price / Book Value ratio x3.42.9 115.4%  
Dividend payout %2.96.2 46.7%   
Avg Mkt Cap Rs m164,44072,300 227.4%   
No. of employees `0009.213.3 69.4%   
Total wages/salary Rs m7,4706,960 107.3%   
Avg. sales/employee Rs Th4,213.92,413.5 174.6%   
Avg. wages/employee Rs Th809.0523.2 154.6%   
Avg. net profit/employee Rs Th745.2152.4 488.8%   
INCOME DATA
Net Sales Rs m38,91132,106 121.2%  
Other income Rs m1,571226 696.1%   
Total revenues Rs m40,48232,332 125.2%   
Gross profit Rs m9,7954,448 220.2%  
Depreciation Rs m2,7721,730 160.3%   
Interest Rs m260241 108.0%   
Profit before tax Rs m8,3342,703 308.3%   
Minority Interest Rs m1630-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,616675 239.3%   
Profit after tax Rs m6,8812,028 339.3%  
Gross profit margin %25.213.9 181.7%  
Effective tax rate %19.425.0 77.6%   
Net profit margin %17.76.3 280.0%  
BALANCE SHEET DATA
Current assets Rs m40,47717,340 233.4%   
Current liabilities Rs m16,7839,559 175.6%   
Net working cap to sales %60.924.2 251.3%  
Current ratio x2.41.8 133.0%  
Inventory Days Days60100 59.4%  
Debtors Days Days8357 145.7%  
Net fixed assets Rs m45,07320,779 216.9%   
Share capital Rs m1,000252 396.2%   
"Free" reserves Rs m47,37724,499 193.4%   
Net worth Rs m48,37724,553 197.0%   
Long term debt Rs m21,0823,517 599.4%   
Total assets Rs m93,94239,595 237.3%  
Interest coverage x33.112.2 270.4%   
Debt to equity ratio x0.40.1 304.2%  
Sales to assets ratio x0.40.8 51.1%   
Return on assets %7.65.7 132.7%  
Return on equity %14.28.3 172.2%  
Return on capital %12.610.5 120.2%  
Exports to sales %048.6 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA15,617 0.0%   
Imports (cif) Rs mNA4,571 0.0%   
Fx inflow Rs m12,98815,617 83.2%   
Fx outflow Rs m7,8995,828 135.5%   
Net fx Rs m5,0899,790 52.0%   
CASH FLOW
From Operations Rs m6,4002,764 231.5%  
From Investments Rs m-4,985-1,432 348.2%  
From Financial Activity Rs m-1,775-1,591 111.5%  
Net Cashflow Rs m-473-259 182.8%  

Share Holding

Indian Promoters % 40.4 45.9 88.0%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 11.4 73.7%  
FIIs % 10.7 25.3 42.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 17.4 114.4%  
Shareholders   109,995 36,892 298.2%  
Pledged promoter(s) holding % 0.0 2.1 1.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  AUROBINDO PHARMA  

Compare BIOCON LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Jun 21, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS